Recent News

• 05.08.2026 - 10-Q - Quarterly report [Sections 13 or 15(d)]
• 04.14.2026 - SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership
• 03.30.2026 - 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
• 02.23.2026 - 8-K - Current report
• 02.23.2026 - Avenue Therapeutics Enters into Exclusive Worldwide License Agreement for ATX-04 for the Treatment of Pompe Disease
• 02.23.2026 - Avenue Therapeutics Enters into Exclusive Worldwide License Agreement for ATX-04 for the Treatment of Pompe Disease
• 02.17.2026 - SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors
• 01.06.2026 - SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership
• 01.06.2026 - 4 - Statement of changes in beneficial ownership of securities
• 12.31.2025 - 8-K - Current report

Recent Filings

• 05.08.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 03.30.2026 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 02.23.2026 - EX-99.1 EX-99.1
• 02.23.2026 - 8-K Current report
• 02.17.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 01.06.2026 - 4 Statement of changes in beneficial ownership of securities
• 01.06.2026 - SCHEDULE 13D/A General Statement of Acquisition of Beneficial Ownership
• 12.31.2025 - 8-K Current report
• 12.16.2025 - EFFECT Notice of Effectiveness